FINWIRES · TerminalLIVE
FINWIRES

Golden Minerals Launches Equity Financing While Subsidiaries Sell Out of Minera William

By

Two wholly-owned subsidiaries of Golden Minerals (AUMN.TO) entered into a definitive agreement to sell their shares in Minera William for US$1.2 million to Streamline Metals Capital and Horizon Silver Resources, the company said overnight Thursday.

Minera William principally held tax losses and a royalty interest in the San Diego project in Mexico, Golden Minerals noted.

Separately, Golden Minerals entered into a private placement equity financing arrangement for $856,463 in gross proceeds.

Under the subscription agreement, Streamline agreed to purchase 3,740,000 common shares of Golden Minerals, priced at $0.229 per share. Upon completion around May 20, Streamline will hold approximately 19.9% of issued and outstanding shares of Golden Minerals.

Golden Minerals plans to use the proceeds from the sale and financing to advance the Sand Canyon project in Nevada and Sarita/Desierto project in Argentina.

The company will also use the funds to evaluate new project opportunities in Bolivia, and for general working capital and corporate purposes.

Shares in AUMN were slightly lower in Canada yesterday.

Related Articles

Mining & Metals

HLS Therapeutics Q1 Net Loss Narrows on Lower Costs, Higher Revenue

HLS Therapeutics (HLS.TO) first-quarter net loss narrowed on lower costs and higher revenue, the company said on Friday.Net loss contracted to US$2.3 million, or US$0.07 per share, from a net loss of US$4.4 million, or US$0.14 per share, in the prior year period. The improvement was due to lower finance and related costs and higher revenue. Analysts polled by FactSet had forecast a loss of US$0.12 per share.Revenue rose 2% to US$12.9 million, up 2% year-over-year, meeting the US$12.9 million forecast. HLS said Vascepa net sales grew 15% to US$4.8 million, the strongest quarterly growth since the second quarter of last year.The company launched its LDL-cholesterol lowering drug Nilemdo in April, which it reported is off to "a positive start" with weekly sales running ahead of forecast.HLS reaffirmed its 2026 consolidated revenue guidance of US$56 million to US$60 million, representing mid-single-digit percentage growth."Q1 results were in line with our expectations and consistent with our annual guidance," said chief executive Craig Millian. "The increase in revenue was driven by Vascepa, which had its strongest quarterly growth since mid-2025 and is a validation of the changes we made to strengthen the cardiovascular sales team last year."HLS shares closed down $0.02, to $4.67, on Thursday on the Toronto Stock Exchange.

$HLS.TO
Mining & Metals

Transat Providing Update On "Volatility" Of Aviation Fuel Prices

$TRZ.TO
Mining & Metals

Earnings Flash (CFF.TO) Conifex Timber Reports Q1 Revenue $21.8M, Down From $44.6M a Year Ago; Net Loss $9.4M or $0.23 Per Share

$CFF.TO